| Name | IPR-803 |
| Description | IPR-803 is an effective inhibitor of the uPAR·uPA protein-protein interaction (PPI) with anti-tumor activity. IPR-803 binds directly to uPAR with a Ki of 0.2 μM. |
| In vitro | IPR-803 (0-200 μM; 3 days) blocks the invasion of MDA-MB-231 cells, and most of the inhibition of cell invasion is unlikely due to the cytotoxicity of the compound. IPR-803 (50 μM; 30 minutes) shows inhibition of MAPK phosphorylation. IPR-803 blocks invasion of breast cancer cells line MDA-MB-231, and inhibits matrix metalloproteinase breakdown of the extracellular matrix. IPR-803 impairs MDA-MB-231 cell adhesion and migration. IPR-803 induces a concentration-dependent impairment of cell adhesion with an IC50 of 30 μM. IPR-803 inhibits MDA-MB-231 cells growth with an IC50 of 58 μM[1]. |
| In vivo | In NSG mice with MDA-MB-231 cells xenograft, IPR-803 (200 mg/kg; i.g.; three times a week; for 5 weeks) impairs breast cancer metastasis with a t1/2 of 5 hours. IPR-803 has a low oral bioavailability at 4 percent, and remains high concentration even after 10 hours in tumor tissue[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 7 mg/mL (15.44 mM), Sonication is recommended.
|
| Keywords | uPAR·uPA protein-protein interaction (PPI) | threoninkinase | Threonine proteases | threonin kinase | Serinekinase | Serine proteases | Serine kinase | Serine endopeptidases | Ser/Thr Protease | PPI | IPR-803 | IPR803 | IPR 803 | Inhibitor | inhibit |
| Inhibitors Related | Trypsin Inhibitor, soybean | Nafamostat mesylate | Lodelaben | AEBSF hydrochloride | Imidazole | p-Aminobenzamidine dihydrochloride | Fasudil hydrochloride | Ceritinib | Proteinase K | Trypsin | FOY 251 | Benzamidine hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Inhibitor Library | PPI Inhibitor Library | Metabolism Compound Library | Bioactive Compounds Library Max | Cell Cycle Compound Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
United States
